Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00219180
- Lead Sponsor
- Novartis
- Brief Summary
To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1797
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after week 8
- Secondary Outcome Measures
Name Time Method Change from baseline in systolic blood pressure after week 8 Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 4 and 8 weeks Blood pressure control target of < 140/90 mmHg after 4 and 8 weeks Evaluate 24-hour ambulatory blood pressure monitoring in a subset of patients
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States